Vanguard Group
BIOA

Vanguard Group’s BioAge Labs BIOA Stock Holding History

Vanguard Group’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$18.7M Sell
1,414,770
-236,477
-14% -$2.1M ﹤0.01% 2644
2025
Q3 		$9.71M Buy
1,651,247
+93,694
+6% +$439K ﹤0.01% 2999
2025
Q2 		$6.43M Buy
1,557,553
+859,886
+123% +$3.46M ﹤0.01% 3118
2025
Q1 		$2.62M Buy
697,667
+340,869
+96% +$1.58M ﹤0.01% 3397
2024
Q4 		$2.07M Buy
356,798
+316,798
+792% +$5.46M ﹤0.01% 3554
2024
Q3 		$832K Buy
+40,000
New +$801K ﹤0.01% 3827

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's BIOA Position: Q4 2025 in Review

Vanguard Group reduced its BioAge Labs (BIOA) stake by 14% in Q4 2025, selling an estimated $2.1M and leaving 1,414,770 shares worth $18.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2644.

Vanguard Group first reported a position in BIOA in Q3 2024 and has held it in 6 quarters since. 114 funds tracked by Wall St. Rank hold BIOA as of Q4 2025.

  • Vanguard Group held 1,414,770 shares of BioAge Labs worth $18.7M as of Q4 2025.
  • Vanguard Group sold 236,477 BioAge Labs shares in Q4 2025, an estimated $2.1M.
  • BioAge Labs made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2644 holding.
  • Vanguard Group first reported a position in BioAge Labs in Q3 2024 and has held it in 6 quarters since.
  • 114 funds tracked by Wall St. Rank held BioAge Labs as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.